Envoy Medical announces release of press statement

Envoy Medical, Inc. Class A

Envoy Medical, Inc. Class A

COCH

0.00
  • Envoy Medical posted a new release on its Acclaim investigational fully implanted cochlear implant pivotal trial.
  • All 56 enrolled patients cleared the three-month follow-up milestone.
  • Six-month follow-ups expected by late 2026; 12-month milestone for the full study targeted for April 2027.
  • Full data planned for inclusion in a future FDA PMA submission.
  • Release: https://www.newsfilecorp.com/release/305827


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607210917NEWSFILECNPR____20260721_305827_1) on July 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.